专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20100215642A1 SYNTHETIC RNA-BASED AGONISTS OF TLR7 失效
标题翻译：合成基于RNA的TLR7激动剂
公开(公告)号：US20100215642A1
公开(公告)日：2010-08-26
申请号：US12703612
申请日：2010-02-10
申请人： Tao Lan , Ekambar Kandimalla , Daqing Wang , Sudhir Agrawal
发明人： Tao Lan , Ekambar Kandimalla , Daqing Wang , Sudhir Agrawal
IPC分类号： A61K39/395 , A61K39/00 , C07H21/02 , A61K31/7125 , A61P35/00 , A61P11/06 , A61P31/00 , A61P17/00
CPC分类号： C12N15/117 , A61K2039/55561 , C12N2310/17 , C12N2310/315 , C12N2310/317 , C12N2310/3183 , C12N2310/333 , C12N2310/51 , C12N2320/31 , C12N2320/51
摘要： The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that selectively induce immune modulatory activity through TLR7.
摘要翻译：本发明涉及新型稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。具体地说，本发明提供了具有改进的核酸酶和核糖核酸酶稳定性的新型基于RNA的寡核糖核苷酸，并通过TLR7选择性诱导免疫调节活性。

12. 发明授权

US08202974B2 Synthetic RNA-based agonists of TLR7 失效
标题翻译： TLR7合成的基于RNA的激动剂
公开(公告)号：US08202974B2
公开(公告)日：2012-06-19
申请号：US12703612
申请日：2010-02-10
申请人： Tao Lan , Ekambar Kandimalla , Daqing Wang , Sudhir Agrawal
发明人： Tao Lan , Ekambar Kandimalla , Daqing Wang , Sudhir Agrawal
IPC分类号： C07H21/02 , C07H21/04 , C12Q1/68 , C12N5/00 , C12N5/02 , A61K49/00 , A61K31/70 , A01N43/04
CPC分类号： C12N15/117 , A61K2039/55561 , C12N2310/17 , C12N2310/315 , C12N2310/317 , C12N2310/3183 , C12N2310/333 , C12N2310/51 , C12N2320/31 , C12N2320/51
摘要： The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA-based oligoribonucleotides with improved nuclease and RNase stability and that selectively induce immune modulatory activity through TLR7.
摘要翻译：本发明涉及稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。具体地，本发明提供了具有改进的核酸酶和RNA酶稳定性的RNA基寡核糖核苷酸，并且通过TLR7选择性诱导免疫调节活性。

13. 发明授权

US08492358B2 Agonists of toll-like receptor 3 and methods of their use 有权
标题翻译：通畅型受体3的激动剂及其使用方法
公开(公告)号：US08492358B2
公开(公告)日：2013-07-23
申请号：US13168494
申请日：2011-06-24
申请人： Ekambar Kandimalla , Tao Lan , Victoria Jane Philbin , Sudhir Agrawal
发明人： Ekambar Kandimalla , Tao Lan , Victoria Jane Philbin , Sudhir Agrawal
IPC分类号： C12N15/11 , A61K49/00
CPC分类号： A61K39/39 , A61K2039/55561 , C12N15/117 , C12N2310/17 , C12N2310/315
摘要： TLR3 agonist compounds, compositions and methods are provided for stimulating the activity of TLR3. The compositions comprise oligonucleotide-based compounds that bind to and activate TLR3. The compositions may also comprise oligonucleotide-based compounds that bind to and activate TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for stimulation of TLR3 activity and for prevention or treatment of diseases wherein modulation of TLR3 activity would be beneficial are provided.
摘要翻译：提供TLR3激动剂化合物，组合物和方法用于刺激TLR3的活性。组合物包含与TLR3结合并激活TLR3的基于寡核苷酸的化合物。组合物还可以包含与其它治疗和/或预防化合物和/或组合物组合结合并活化TLR3的基于寡核苷酸的化合物。提供了使用这些化合物和组合物刺激TLR3活性和预防或治疗TLR3活性调节有益的疾病的方法。

14. 发明申请

US20130142778A1 COMPOSITIONS FOR INHIBITING GENE EXPRESSION AND USES THEREOF 有权
标题翻译：用于抑制基因表达的组合物及其用途
公开(公告)号：US20130142778A1
公开(公告)日：2013-06-06
申请号：US13072017
申请日：2011-03-25
申请人： SUDHIR AGRAWAL , EKAMBAR KANDIMALLA , MALLIKARJUNA PUTTA , Ireneusz Nowak , Nicola LaMonica , Weiwen Jiang , Michael Reardon , Tao Lan
发明人： SUDHIR AGRAWAL , EKAMBAR KANDIMALLA , MALLIKARJUNA PUTTA , Ireneusz Nowak , Nicola LaMonica , Weiwen Jiang , Michael Reardon , Tao Lan
IPC分类号： C12N15/113 , A61K39/35 , A61K39/395 , A61K38/02 , A61K31/7088 , A61K39/00
CPC分类号： C12N15/113 , A61K31/7088 , A61K31/7105 , A61K31/712 , A61K31/713 , A61K38/02 , A61K39/00 , A61K39/35 , A61K39/395 , A61K45/06 , C12N15/111 , C12N15/1138 , C12N2310/113 , C12N2310/14 , C12N2310/317 , C12N2310/318 , C12N2310/344 , C12N2310/50 , C12N2310/51 , C12N2310/52 , C12N2320/30
摘要： The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.
摘要翻译：本发明人已经研究了提供更有效的miRNA阻断化合物的方法。本发明人已经发现了惊人地改善miRNA阻断分子的功效的新结构特征。这些特征包括多个3'末端的存在和在5'端的接头。令人惊讶的是，这些特征以降低化合物生物学不稳定性的方式提高了基因表达阻断化合物的功效。更令人惊奇的是，这种效应已被发现适用于基于DNA和RNA的寡核苷酸类化合物，并且应用于传统的反义和RNAi技术。

15. 发明授权

US08877722B2 Compositions for inhibiting gene expression and uses thereof 有权
标题翻译：用于抑制基因表达的组合物及其用途
公开(公告)号：US08877722B2
公开(公告)日：2014-11-04
申请号：US13072017
申请日：2011-03-25
申请人： Sudhir Agrawal , Ekambar Kandimalla , Mallikarjuna Putta , Ireneusz Nowak , Nicola LaMonica , Weiwen Jiang , Michael Reardon , Tao Lan
发明人： Sudhir Agrawal , Ekambar Kandimalla , Mallikarjuna Putta , Ireneusz Nowak , Nicola LaMonica , Weiwen Jiang , Michael Reardon , Tao Lan
IPC分类号： A61K48/00 , C07H21/02 , C07H21/04
CPC分类号： C12N15/113 , A61K31/7088 , A61K31/7105 , A61K31/712 , A61K31/713 , A61K38/02 , A61K39/00 , A61K39/35 , A61K39/395 , A61K45/06 , C12N15/111 , C12N15/1138 , C12N2310/113 , C12N2310/14 , C12N2310/317 , C12N2310/318 , C12N2310/344 , C12N2310/50 , C12N2310/51 , C12N2310/52 , C12N2320/30
摘要： The inventors have examined the means for providing more efficacious miRNA blocking compounds. The inventors have discovered new structural features that surprisingly improve the efficacy of miRNA blocking molecules. These features include the presence of multiple 3′ ends and a linker at the 5′ ends. Surprisingly, these features improve the efficacy of the gene expression blocking compounds in a manner that decreases the compound's biologic instability. Even more surprisingly, this effect has been found to be applicable to both DNA and RNA oligonucleotide-based compounds and to have application in traditional antisense and RNAi technology.
摘要翻译：本发明人已经研究了提供更有效的miRNA阻断化合物的方法。本发明人已经发现了惊人地改善miRNA阻断分子的功效的新结构特征。这些特征包括多个3'末端的存在和在5'端的接头。令人惊讶的是，这些特征以降低化合物生物学不稳定性的方式提高了基因表达阻断化合物的功效。更令人惊奇的是，这种效应已被发现适用于基于DNA和RNA的寡核苷酸类化合物，并且应用于传统的反义和RNAi技术。

16. 发明授权

US06914052B2 Selective anti-viral nucleoside chain terminators 有权
标题翻译：选择性抗病毒核苷链终止子
公开(公告)号：US06914052B2
公开(公告)日：2005-07-05
申请号：US10097672
申请日：2002-03-13
申请人： Larry W. McLaughlin , Andrew W. Fraley , DongLi Chen , Tao Lan
发明人： Larry W. McLaughlin , Andrew W. Fraley , DongLi Chen , Tao Lan
IPC分类号： A61K31/70 , A61P31/12 , C07D471/02 , C07H19/048 , C07H19/052 , C07H19/06 , C07H19/10 , C07H19/23
CPC分类号： C07H19/048 , C07H19/052 , C07H19/06 , C07H19/10 , C07H19/23
摘要： The present invention relates to dideoxynucleoside analog compounds containing a dideoxy ribofuranosyl moiety that exhibit selective anti-viral activity coupled with substantially low toxicity toward the host cells. In particular, the compounds according to the present invention show potent inhibition of the replication of the human immunodeficiency virus (HIV), while remaining substantially inert toward host cell DNA. Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of retroviruses, particularly HIV. The compounds of the invention comprise a (2,3′-dideoxy-β-ribofuranosyl) ring coupled to a heterocyclic nucleobase that lacks an “O2 carbonyl”, that enables them to selectively react with and inhibit viral reverse transcriptase, while remaining substantially unreactive toward human DNA polymerases.
摘要翻译：本发明涉及含有双脱氧呋喃核糖基部分的双脱氧核苷类似物化合物，其表现出选择性抗病毒活性，同时对宿主细胞具有显着低毒性。特别地，根据本发明的化合物显示出有效抑制人免疫缺陷病毒（HIV）的复制，同时对宿主细胞DNA保持基本上惰性。根据本发明的化合物表现出用于抑制逆转录病毒，特别是HIV的生长或复制的药剂的主要用途。本发明的化合物包含偶联到缺少“O 2羰基”的杂环核碱基的（2,3'-二脱氧-β-呋喃核糖基）环，其使得它们能够选择性地与病毒逆转录酶反应并抑制病毒逆转录酶，同时保持基本上不反应针对人类DNA聚合酶。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式